BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 11717012)

  • 1. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy.
    Voltolini L; Luzzi L; Ghiribelli C; Paladini P; Di Bisceglie M; Gotti G
    Eur J Cardiothorac Surg; 2001 Dec; 20(6):1106-12. PubMed ID: 11717012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
    Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR
    Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
    Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
    Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group.
    Johnstone DW; Byhardt RW; Ettinger D; Scott CB
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):365-9. PubMed ID: 12243809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
    Nagai K; Tsuchiya R; Mori T; Tada H; Ichinose Y; Koike T; Kato H;
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):254-60. PubMed ID: 12579093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes.
    Billiet C; De Ruysscher D; Peeters S; Decaluwé H; Vansteenkiste J; Dooms C; Deroose CM; De Leyn P; Hendrikx M; Bulens P; Le Péchoux C; Mebis J
    J Thorac Oncol; 2016 Sep; 11(9):1538-49. PubMed ID: 27374454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.
    Strauss GM; Herndon JE; Sherman DD; Mathisen DJ; Carey RW; Choi NC; Rege VB; Modeas C; Green MR
    J Clin Oncol; 1992 Aug; 10(8):1237-44. PubMed ID: 1321893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
    Albain KS; Rusch VW; Crowley JJ; Rice TW; Turrisi AT; Weick JK; Lonchyna VA; Presant CA; McKenna RJ; Gandara DR
    J Clin Oncol; 1995 Aug; 13(8):1880-92. PubMed ID: 7636530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
    Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H
    J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group.
    Vansteenkiste JF; De Leyn PR; Deneffe GJ; Lievens YN; Nackaerts KL; Van Raemdonck DE; van der Schueren E; Lerut TE; Demedts MG
    Ann Oncol; 1998 Mar; 9(3):261-7. PubMed ID: 9602259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).
    Van Zandwijk N; Smit EF; Kramer GW; Schramel F; Gans S; Festen J; Termeer A; Schlosser NJ; Debruyne C; Curran D; Giaccone G
    J Clin Oncol; 2000 Jul; 18(14):2658-64. PubMed ID: 10894864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
    Burkes RL; Ginsberg RJ; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Cooper JD
    J Clin Oncol; 1992 Apr; 10(4):580-6. PubMed ID: 1312587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.
    Sawabata N; Keller SM; Matsumura A; Kawashima O; Hirono T; Osaka Y; Maeda H; Fukai S; Kawahara M;
    Lung Cancer; 2003 Oct; 42(1):69-77. PubMed ID: 14512190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
    Jaklitsch MT; Herndon JE; DeCamp MM; Richards WG; Kumar P; Krasna MJ; Green MR; Sugarbaker DJ
    J Surg Oncol; 2006 Dec; 94(7):599-606. PubMed ID: 17039491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
    Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.